Post by marriott on Aug 28, 2022 14:06:50 GMT
Billy :
Correct , the issue is not with the product and it also is not demand for its product going forward . The reasons were stated .
You write " Novavax can not increase demand for their product if everyone that wants a COVID vaccine already has one. The ability to drive demand is outside of their control. "
There's broad consensus that despite the benefit of the currently available vaccines, Fauci said recently the "job is not done " .
Given a need , the ability to drive demand is certainly inside the control of vaccine companies . Here are some of the examples that I would instruct a new Novavax leadership to consider when evaluating future need and demand :
A pan-coronavirus vaccine that protects equally against all variants .
Vaccines that stop infections from happening during the appropriate formative development .
Since viruses enter through the nose , work on a mucosal vaccine vaccine that would be sprayed into nose .
A small patch that would be applied to the skin and carry the vaccine in microneedles.
The point is get the necessary licenses to sell current vaccines which are injected and produce an antibody response throughout the body. This is definitely needed to gain earnings and revenue . Novavax may have been late for the first " SHOT " at the coronavirus so unstoppable leadership and work on other vaccines that do not require shots so they do not miss the next wave.
The pandemic narrative may be changing but containing transmissible viruses are limited !
Correct , the issue is not with the product and it also is not demand for its product going forward . The reasons were stated .
You write " Novavax can not increase demand for their product if everyone that wants a COVID vaccine already has one. The ability to drive demand is outside of their control. "
There's broad consensus that despite the benefit of the currently available vaccines, Fauci said recently the "job is not done " .
Given a need , the ability to drive demand is certainly inside the control of vaccine companies . Here are some of the examples that I would instruct a new Novavax leadership to consider when evaluating future need and demand :
A pan-coronavirus vaccine that protects equally against all variants .
Vaccines that stop infections from happening during the appropriate formative development .
Since viruses enter through the nose , work on a mucosal vaccine vaccine that would be sprayed into nose .
A small patch that would be applied to the skin and carry the vaccine in microneedles.
The point is get the necessary licenses to sell current vaccines which are injected and produce an antibody response throughout the body. This is definitely needed to gain earnings and revenue . Novavax may have been late for the first " SHOT " at the coronavirus so unstoppable leadership and work on other vaccines that do not require shots so they do not miss the next wave.
The pandemic narrative may be changing but containing transmissible viruses are limited !